ImmuCell (ICCC)
Makes First Defense antibody products to prevent scours in newborn dairy and beef calves.
Something off on this page? Send us feedback.
First Defense is a USDA-licensed line of oral bovine-antibody products sold to dairy and beef producers through distributors. The company also reports a Mastitis segment, but has shifted active manufacturing and sales focus toward calf health.
First Defense is ImmuCell's core commercial franchise: orally delivered bovine antibodies intended to prevent scours in newborn dairy and beef calves. The line has formulations targeting E. coli, coronavirus, and rotavirus, and reaches producers through veterinarians and distributors.
The Scours segment is centered on First Defense. The Mastitis segment includes the California Mastitis Test line, which uses reagents and equipment to identify mastitic quarters. Re-Tain remains in stability and investigational testing rather than active FDA-approval work.
North America is the primary market, with sales also made in selected international regions. The current strategy centers on First Defense sales and on refitting former Re-Tain manufacturing capacity for First Defense production.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $8.9M · Total debt $12.4M · Total assets $46.6M · Shareholders' equity $31.4M
- Revenue
- $7.2M
- Operating income
- $1.9M
- Net income
- $1.8M
No dividends on record.
| Institutions | 14.68% | 1.33M shares | |
|---|---|---|---|
| 31 holders · as of Jun 30, 2026 | |||
| Insiders | 20.06% | 1.82M shares | |
| 7 holders · as of Jun 22, 2026 | |||
| Other | 65.26% | 5.93M shares | |
| remainder | |||
9.08M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Ejnar A. Knudsen IIIInsider | 9.17% | 832,790 | filed Nov 20, 2025 |
Norman H. Pessin1Insider | 7.75% | 703,636 | filed Apr 16, 2021 |
Vanguard Capital Management LLCInstitution | 2.95% | 268,130 | as of Jun 30, 2026 |
Morgan StanleyInstitution | 2.58% | 233,910 | as of Jun 30, 2026 |
Michael F. BrighamInsiderdirector | 2.26% | 205,700 | filed Mar 24, 2026 |
- Norman H. Pessin's transaction reports restate only vehicles that traded; the 2021 ownership statement (703.6K) is used instead.
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jun 18, 2026 | Boekhorst Paul Francis Olivier te | director, officer: President and CEO | +8,000 | $9.50 |
| Dec 3, 2025 | Boekhorst Paul Francis Olivier te | director, officer: President and CEO | +9,675 | $5.03 |
| Dec 4, 2025 | Boekhorst Paul Francis Olivier te | director, officer: President and CEO | +2,432 | $5.50 |
| Dec 2, 2025 | Boekhorst Paul Francis Olivier te | director, officer: President and CEO | +3,708 | $4.87 |
| Nov 25, 2025 | David Scott Tomsche | director | +3,266 | $4.76 |
- Zoetis
Direct calf- and dam-level newborn-scours vaccine alternative
- Elanco Animal Health
Maternal vaccine alternative for multi-pathogen calf scours
- Merck
Maternal and intranasal vaccine alternatives for calf scours
CompareAfter hours
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| ImmuCell | $9.99 | +0.60% | $91.6M | 119.7 | — | 3.0 | +11.5% |
| Zoetis | $72.86 | +0.02% | $29.90B | 11.8 | 11.7 | 3.1 | +0.3% |
| Elanco Animal Health | $22.93 | +0.04% | $11.20B | — | 19.3 | 2.2 | +10.2% |
| Merck | $150.94 | +0.02% | $369.24B | 119.6 | 17.5 | 5.6 | +5.1% |
| Median | 65.7 | 17.5 | 3.1 | +5.1% |